Vaiman, E.E.,
Shnayder, N.A.,
Zhuravlev, N.M.,
Petrova, M.M.,
Asadullin, A.R.,
Al-Zamil, M.,
Garganeeva, N.R.,
Shipulin, G.A.,
Cumming, G.,
Nasyrova, R.F. (2022) (
low, moderate, high). We
recommend implementation in
protocols of primary diagnosis of AP-induced LQTS
Zelinska, N.,
Iotova, V.,
Skorodok, J.,
Malievsky, O.,
Peterkova, V.,
Samsonova, L.,
Rosenfeld, Ron G.,
Zadik, Zvi,
Jaron-Mendelson, Michal,
Koren, Ronit,
Amitzi, Leanne,
Raduk, Dmitri,
Hershkovitz, Oren,
Hart, Gili (2017) low compliance as a result of inconvenience and distress in patients.
Objective: C-terminal peptide
Introduction: Due to severe burden of depressive disorders and a
low rate of remission in patients
neurotransmission and MAO-inhibiting activity. The results indicated that M-20 was promising (at the
low dose